PARP1 Bound by Zejula

Zejula (Niraparib)

ZEJULA is the only PARP inhibitor that has demonstrated a clinically meaningful increase in progression-free survival (PFS) in women with recurrent ovarian cancer, regardless of BRCA mutation or biomarker status, in a randomized, prospectively designed Phase 3 clinical trial. ZEJULA offers oral, once-daily dosing, enabling convenient administration for maintenance treatment.

3D Molecular Visualization

This is a 3D molecular visualization of  Poly(ADP-ribose) Polymerase (PARP1) bound by its inhibitor Zejula.

Purchase 3D print

If you’d like to purchase a 3D print of PARP1 bound by Zejula, then please visit our store where you can purchase a 3D print directly. Models are available in multiple sizes. Please contact us if you’d like to request something specific.

No comments yet.

Leave a Reply

Powered by WordPress. Designed by WooThemes